Urban and Insular Study on Treatment Experiences and Stigma in People Living with HIV
SUNRISE
Clinical Characterization and Cross-Sectional Comparison of Stigma, Mental Health, and Treatment Experience Among People Living with HIV in Urban and Insular Settings in Portugal
1 other identifier
observational
300
1 country
1
Brief Summary
Study Title: SUNRISE Study: Urban and Island Experiences of HIV Treatment and Stigma What is this study about? This study aims to understand how living in urban areas versus islands affects the experiences of people living with HIV (PLWH) in Portugal. Specifically, the investigators want to explore how stigma and mental health (such as depression and anxiety) differ between these two settings. The investigators are also interested in understanding how the number of pills a person takes daily (called "pill burden") impacts their mental health and satisfaction with treatment. Why is this study important? Stigma related to HIV can make it harder for people to stick to their treatment and can negatively affect their mental health and overall well-being. By comparing urban and island settings, the investigators hope to identify unique challenges faced by PLWH in different environments. This information will help the investigators to develop better strategies to support people living with HIV, no matter where they live. Who can participate? Adults (18 years or older) who have been diagnosed with HIV. People who have been on antiretroviral therapy (HIV treatment) for at least six months. Individuals living in urban areas or island region. What will happen during the study? Participants will complete a one-time interview during their regular HIV care visit. The interview will include questions about: Their experiences with HIV-related stigma. Their mental health (including depression and anxiety). Their satisfaction with their current HIV treatment. The number of pills they take daily and how this affects their daily life. All information will be kept confidential, and participation is voluntary. What are the potential benefits of participating? This study will help to understand the challenges faced by people living with HIV in different parts of Portugal. This knowledge can lead to improved support services and treatment options for PLWH in the future. What are the risks of participating? There are no physical risks associated with this study. However, some questions may touch on sensitive topics, such as stigma or mental health. How will the results be used? The results of this study will be shared with the scientific community, healthcare providers, and organizations that support people living with HIV. The goal is to use this information to improve care and reduce stigma for PLWH in Portugal and beyond. Who is conducting this study? This study is led by researchers from the Faculty of Medicine of Lisbon, in collaboration with hospitals in Portugal mainland, the Azores, and Madeira.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2025
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 1, 2025
CompletedFirst Posted
Study publicly available on registry
February 6, 2025
CompletedStudy Start
First participant enrolled
March 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 27, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
February 27, 2026
CompletedFebruary 19, 2025
February 1, 2025
12 months
February 1, 2025
February 15, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Levels of HIV-Related Stigma in Urban versus Island Settings
This outcome measures the levels of HIV-related stigma experienced by individuals living with HIV (PLWH) in urban and island settings in Portugal. Stigma is assessed using a validated HIV Stigma Scale, which evaluates perceived and internalized stigma (range: 0-48, where higher scores indicate greater perceived stigma). The results will be compared between the two geographic cohorts to identify differences in stigma experiences.
Cross-sectional assessment at baseline (one-time measurement during study enrollment).
Secondary Outcomes (5)
Prevalence of Depression and Anxiety in Urban versus Island PLWH
Cross-sectional assessment at baseline (one-time measurement during study enrollment).
Association Between Stigma and Mental Health Indicators (Depression and Anxiety)
Cross-sectional assessment at baseline (one-time measurement during study enrollment).
Association Between Pill Burden and Mental Health Impact in People Living With HIV
Cross-sectional assessment at baseline (one-time measurement during study enrollment).
Association Between HIV Treatment Satisfaction and Stigma/Mental Health Indicators
Cross-sectional assessment at baseline (one-time measurement during study enrollment).
Assessment and comparison of HIV-Related Knowledge between Urban versus Island Settings
Cross-sectional assessment at baseline (one-time measurement during study enrollment).
Study Arms (2)
Urban Cohort
People living with HIV (PLWH) who receive care in urban centers.
Island Cohort
People living with HIV (PLWH) who receive care in island regions (Azores and Madeira).
Eligibility Criteria
The study population consists of individuals living with HIV (PLWH) who are receiving care in urban and island settings in Portugal. Participants must be 18 years of age or older, diagnosed with HIV, and on antiretroviral therapy (ART) for at least six months. They must also be on a daily oral treatment regimen (single or multiple pills) and able to provide informed consent.
You may qualify if:
- Individuals diagnosed with HIV
- Aged 18 years or older.
- On antiretroviral therapy (ART) for at least six months.
- On a daily oral treatment regimen (single or multiple pills).
- Able to provide informed consent.
You may not qualify if:
- Individuals under 18 years of age.
- Individuals who have switched antiretroviral regimen in the previous six months.
- Individuals unable to provide informed consent (e.g., due to cognitive impairment or lack of capacity).
- Individuals with limited understanding of the study procedures or questionnaires (e.g., language barriers or cognitive limitations).
- Individuals who are incarcerated or deprived of liberty.
- Pregnant individuals.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Unidade Local de Saúde de Santa Maria
Lisbon, Portugal
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
February 1, 2025
First Posted
February 6, 2025
Study Start
March 1, 2025
Primary Completion
February 27, 2026
Study Completion
February 27, 2026
Last Updated
February 19, 2025
Record last verified: 2025-02
Data Sharing
- IPD Sharing
- Will not share